PT  - JOURNAL ARTICLE
AU  - Houlihan, Catherine F
AU  - Vora, Nina
AU  - Byrne, Thomas
AU  - Lewer, Dan
AU  - Heaney, Judith
AU  - Moore, David A.
AU  - Matthews, Rebecca
AU  - Adam, Sajida
AU  - Enfield, Louise
AU  - Severn, Abigail
AU  - McBride, Angela
AU  - Spyer, Moira
AU  - Beale, Rupert
AU  - Cherepanov, Peter
AU  - Gaertner, Kathleen
AU  - Edwards, Sarah
AU  - Shahmanesh, Maryam
AU  - Ng, Kevin
AU  - Faulkner, Nikhil
AU  - Cornish, Georgina
AU  - Walker, Naomi
AU  - Michie, Susan
AU  - Manley, Ed
AU  - Lorencatto, Fabiana
AU  - Gilson, Richard
AU  - Gandhi, Sonia
AU  - Gamblin, Steve
AU  - Kassiotis, George
AU  - McCoy, Laura E
AU  - Swanton, Charles
AU  - Hayward, Andrew
AU  - Nastouli, Eleni
TI  - SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study
AID  - 10.1101/2020.06.08.20120584
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.08.20120584
4099  - http://medrxiv.org/content/early/2020/06/09/2020.06.08.20120584.short
4100  - http://medrxiv.org/content/early/2020/06/09/2020.06.08.20120584.full
AB  - Background Although SARS-CoV-2 infection in Healthcare Workers (HCWs) is a public health concern, there is little description of their longitudinal antibody response in the presence or absence of SARS-CoV-2 and symptoms. We followed HCWs in an acute London hospital to measure seroconversion and RNA detection at the peak of the pandemic.Methods We enrolled 200 patient-facing HCWs between 26 March and 8 April 2020 and collected twice-weekly self-administered nose and throat swabs, symptom data and monthly blood samples. Swabs were tested for SARS-CoV-2 by PCR, and serum for antibodies to spike protein by ELISA and flow cytometry.Findings During the first month, 42/200 (21%) HCWs were PCR positive in at least one nose and throat swab. Only 8/42 HCW (19%) who were PCR positive during the study period had symptoms that met current case definition. Of 181 HCWs who provided enrollment and follow-up blood samples, 82/181 (45.3%) were seropositive. In 33 HCWs who had positive serology at baseline but were PCR negative, 32 remained PCR negative. One HCW had a PCR positive swab six days after enrollment, likely representing waning infection.Conclusion The high seropositivity and RNA detection in these front-line HCWs brings policies to protect staff and patients into acute focus. Our findings have implications for planning for the ‘second wave’ and for vaccination campaigns in similar settings. The evidence of asymptomatic SARS-CoV-2 infection indicates that asymptomatic HCW surveillance is essential, while our study sets the foundations to answer pertinent questions around the duration of protective immune response and the risk of re-infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by the UCLH/UCL NIHR Biomedical Research Centre and funding from the MRC UKRI grant ref: MC_PC_19082. The work was additionally supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK, the UK Medical Research Council, and the Wellcome Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NHS Health Research Authority (ref 20/SC/0147) on 26 March 2020. Ethical oversight was provided by the South Central Berkshire Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo external datasets